Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Empirical Formula (Hill Notation):
C35H36F3N3O4
CAS Number:
Molecular Weight:
619.67
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77
MDL number:
Product Name
GW6471, ≥98% (HPLC)
Quality Level
assay
≥98% (HPLC)
form
powder
storage condition
desiccated
color
white to beige
solubility
DMSO: 5 mg/mL, clear (warmed)
originator
GlaxoSmithKline
storage temp.
2-8°C
SMILES string
CCC(=O)NC[C@H](Cc1ccc(OCCc2nc(oc2C)-c3ccccc3)cc1)N\C(C)=C/C(=O)c4ccc(cc4)C(F)(F)F
InChI
1S/C35H36F3N3O4/c1-4-33(43)39-22-29(40-23(2)20-32(42)26-12-14-28(15-13-26)35(36,37)38)21-25-10-16-30(17-11-25)44-19-18-31-24(3)45-34(41-31)27-8-6-5-7-9-27/h5-17,20,29,40H,4,18-19,21-22H2,1-3H3,(H,39,43)/b23-20-/t29-/m0/s1
InChI key
TYEFSRMOUXWTDN-DYQICHDWSA-N
General description
GW6471 prevents apoptosis and cell cycle arrest at G0/G1 in renal cell carcinoma. It reduces enhanced fatty acid oxidation and oxidative phosphorylation associated with glycolysis inhibition.
Application
GW6471 has been used:
- to investigate the role of peroxisome proliferator-activated receptors (PPARs) alpha in perfluorooctanoic acid (PFOA) induced developmental cardiotoxicity
- to abolish the protection of bezafibrate (BZA) against hypertrophy
- to block the enhanced activity of the hepatitis B virus (HBV) core promoter
Biochem/physiol Actions
GW6471 is a PPARα antagonist, which completely inhibits GW409544-induced activation of PPARα with an IC50 = 0.24 μM. GW6471 induces a PPARα conformation that interacts efficiently with co-repressors.
Features and Benefits
This compound is a featured product for Gene Regulation research. Click here to discover more featured Gene Regulation products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
This compound is featured on the Nuclear Receptors (PPARs) page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
dust mask type N95 (US), Eyeshields, Gloves
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Hongliang Li et al.
European journal of pharmacology, 812, 155-162 (2017-07-19)
We examined the effects of the PPARα activator fenofibrate on voltage-dependent K
Shiori Ikeguchi et al.
Journal of pharmacological sciences, 138(1), 9-15 (2018-09-24)
10-oxo-trans-11-octadecenoic acid (KetoC) and 10-hydroxy-cis-12-octadecenoic acid (HYA) are long-chain fatty acids generated from linoleic acid by the gut lactic acid bacterium Lactobacillus plantarum. These fatty acids have been reported to have anti-inflammatory activity in the intestine. However, little is known
PPARalpha inhibition modulates multiple reprogrammed metabolic pathways in kidney cancer and attenuates tumor growth
Abu AO, et al.
American Journal of Physiology. Cell Physiology, 308(11), C890-C898 (2015)